Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy
- 4 September 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 12225-12236
Abstract
Several chemoimmunotherapy regimens have been approved by the U.S. FDA, verifying the great clinical value and potential of the strategy. However, the immunomodulatory function of chemotherapy was insufficient, which did not provide extra overall survival benefits, especially in a head-to-head comparison of chemoimmunotherapy versus immunotherapy. Here, we engineered twin and triplet drugs derived from an immunogenic chemotherapeutic drug (oxaliplatin) and small-molecule inhibitors of negative immunoregulation pathways (COX2 and IDO) in tumors as an improved chemotherapeutic component within chemoimmunotherapy. The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. Mechanistic analyses revealed that the drug induced immunogenic cell death and restored tumor immune microenvironment toward tumor clearance in vivo, resulting in a great decrease in tumor-infiltrating Tregs and an increase in the CD8+ T/Treg ratio when combined with anti-PD-1. Our work expands the application of platinum twin drugs in combination with an immune checkpoint blockade.Keywords
Funding Information
- University of Science and Technology of China (KJ2060190030, KY2060000124)
- Fundamental Research Funds for the Central Universities (WK2060190101, WK9110000144, WY2060190092)
- National Natural Science Foundation of China (31971299, GG2060190386, GG2065010001)
This publication has 49 references indexed in Scilit:
- The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cellsChemical Communications, 2014
- The Prodrug Platin‐A: Simultaneous Release of Cisplatin and AspirinAngewandte Chemie International Edition, 2014
- Synthetic Methods for the Preparation of Platinum Anticancer ComplexesChemical Reviews, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Perspective: Combined forcesNature, 2013
- Immunogenic cell death and DAMPs in cancer therapyNature Reviews Cancer, 2012
- Role of Vitamin and Mineral Supplementation and Aspirin Use in Cancer SurvivorsJournal of Clinical Oncology, 2010
- Homo and Heterodimer Ligands: the Twin Drug Approach2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitroCancer Chemotherapy and Pharmacology, 2005